Trials / Unknown
UnknownNCT02909088
Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering).
An Open-label Study to Evaluate the Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering).
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Gerald Maguire, MD · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the efficacy and tolerability of ecopipam in reducing stuttering symptoms. It is hypothesized that ecopipam effectively reduces stuttering symptoms as measured on the SSI-IV total score, the CGI, SSS and OASES.
Conditions
- Stuttering, Adult
- Childhood-onset Fluency Disorder
- Speech Disorders
- Language Disorders
- Communication Disorder
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ecopipam 50mg | |
| DRUG | Ecopipam 100mg |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2017-08-01
- Completion
- 2017-11-01
- First posted
- 2016-09-21
- Last updated
- 2016-10-26
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02909088. Inclusion in this directory is not an endorsement.